-
Mashup Score: 2Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma - 1 month(s) ago
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Novel BTK Inhibitor LP-168 Under Investigation in China for R/R Mantle Cell Lymphoma - 2 month(s) ago
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma. #lymsm #oncology https://t.co/R2jBMQYJKT
-
-
Mashup Score: 1Novel BTK Inhibitor LP-168 Under Investigation in China for R/R Mantle Cell Lymphoma - 2 month(s) ago
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma. #lymsm #oncology https://t.co/R2jBMQYJKT
-
-
Mashup Score: 3TakeAim Lymphoma Tests Proof of Concept for Dual IRAK4/FLT3 Blockade in B-Cell Malignancy Treatment - 2 month(s) ago
Targeting IRAK4 with emavusertib could be a viable treatment option that offers needed blood-brain barrier penetration in PCNSL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Combining the IRAK4 and FLT3 inhibitor emavusertib with a BTK inhibitor has the potential to create a new successful approach for treating patients with primary central nervous system lymphoma. @GregNowakowski @MayoClinic #lymsm #oncology https://t.co/VZ8sWnPgoL https://t.co/QEHQVihhlC
-
-
Mashup Score: 5
Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy #lymsm #oncology https://t.co/RARoUWsiJz
-
-
Mashup Score: 5
Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy #lymsm #oncology https://t.co/RARoUWsiJz
-
-
Mashup Score: 5
Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy #lymsm #oncology https://t.co/RARoUWsiJz
-
-
Mashup Score: 0EU Greenlights Odronextamab for R/R Follicular Lymphoma and DLBCL - 3 month(s) ago
The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
EU Greenlights Odronextamab for R/R Follicular Lymphoma and DLBCL #lymsm #oncology https://t.co/sfHWWlV0IR
-
-
Mashup Score: 1
The NCCN Clinical Practice Guidelines in Oncology now list denileukin diftitox as an appropriate option for patients with cutaneous T-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
.@NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology #lymsm #oncology https://t.co/B0z54zSCjc
-
-
Mashup Score: 5
Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy #lymsm #oncology https://t.co/RARoUWsiJz
-
Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma @FrontImmunol #lymsm #oncology https://t.co/xeDRFowc6u